Venture capital fund · 1 deal
Every published round Genesis Fund took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| PredicTx | Pre-seed | 17 Oct 2025 | $1.6m | Lead | Women's Agenda, Startup Daily (17 Oct 2025), Startup Daily (17 Oct 2025) |
Companies Genesis Fund has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| PredicTx | AI-powered oncology platform for precise chemotherapy dosing | 17 Oct 2025, Pre-seed | 1 | 1 |
Fund closes reported for Genesis Fund, as distinct from the investments it has made.
Companies Genesis Fund has backed that another company then bought. An exit for the holding, not a deal Genesis Fund did.
Stories naming Genesis Fund. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures announces it has fully wound down its 1998 biotech fund with returns in the top quartile of US peers, recalling portfolio listings, Dynamic Hearing's sale to Wolfson, and its $122.5m fourth fund.
GBS Venture Partners closed its third life science fund at $145 million, exceeding its $120 million target, with backing from returning and new Australian institutional investors.